[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524093":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":57,"collaborators":61,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":23,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":23,"overallStatus":38,"whyStopped":23,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Duke University","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Idiopathic Pulmonary Arterial Hypertension","Arm 1... patients with IPAH",[12],"Drug: 129Xe Hyperpolarized",{"label":14,"type":6,"description":15,"interventionNames":16},"Pulmonary Arterial Hypertension Associated with Connective Tissue Disease","Arm 2... patients with CTD-PAH",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","129Xe Hyperpolarized","Each xenon dose will be limited to a volume less than 25% of a subject's total lung capacity (TLC), as is the case for all protocols currently carried out under IND 109490",[9,14],null,[25],{"name":26,"affiliation":27,"role":28},"Fawaz Alenezi, MD","Duke Univeristy","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":23,"email":34},"Claudia Salazar","CONTACT","+1 919 660 2026","claudia.salazar@duke.edu",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Duke University Medical Center","RECRUITING","Durham","North Carolina","27710","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-78.89862,35.99403,{"lat":48,"lon":47},[51,55],{"name":52,"role":32,"phone":53,"phoneExt":23,"email":54},"David Ptashnik","9196682642","david.ptashnik@duke.edu",{"name":56,"role":28,"phone":23,"phoneExt":23,"email":23},"Fawaz A Alenezi, MD",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"SPONSOR_INVESTIGATOR","Bastiaan Driehuys","Professor of Radiology",[62],{"name":63,"class":6},"American Heart Association","100524093","phase-2-129-xenon-mri-as-a-biomarker-for-diagnosis-and-response-to-therapy-in-pulmonary-arterial-hypertension-pah-100524093",false,"NCT06104228","129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)","Xenon PAH Bio","Inclusion Criteria:\n\nArm 1 -IPAH\n\n* Age: 18-75 years\n* WHO functional class 2 or 3\n* Mean pulmonary artery pressures \\> 20 mmHg\n* Pulmonary capillary wedge pressure ≤15 mmHg\n* Pulmonary vascular resistance \\> 2 Wood Units (WU)\n* No other cause identified for PAH\n\nArm 2 -PAH-CTD\n\n* Age: 18-75 years\n* WHO functional class (FC) 2 or 3\n* Mean pulmonary artery pressures \\> 20 mmHg\n* Pulmonary capillary wedge pressure ≤15 mmHg\n* Pulmonary vascular resistance \\> 2 WU\n* Diagnosis of connective tissue disease\n\nExclusion Criteria:\n\n* PH other than Idiopathic PAH or PAH associated with CTD; any conditions that prevent the performance of 129Xe MRI scans will be excluded from the study.","ALL","18 Years","75 Years",{"count":75,"type":76},20,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).",[82,9,83,84],"Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)","Connective Tissue Diseases","2026-02-23",{"date":87,"type":88},"2026-02-24","ACTUAL",{"date":90,"type":88},"2024-08-12",{"date":92,"type":76},"2027-03-31",{"name":59,"class":6},1]